Vertex Pharmaceuticals Inc
VRTX· Nasdaq
Released Nov 3, 2025, after the close
10-Q filed Nov 4, 2025, 35 days after period end · 0000875320-25-000232
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $3.08B | $2.77B | $2.48B | $2.33B |
| Net Income | $1.08B | $1.05B | $1.04B | $930.50M |
| EPS Diluted |
Vertex Pharmaceuticals Inc · CIK 875320 · Engraved from SEC EDGAR
| $4.20 |
| $4.01 |
| $3.97 |
| $3.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.